[see Indications and Usage (1.1) and Clinical Pharmacology (12.3)]
Infection* | Recommended Dose/Duration of Therapy |
---|---|
| |
Community-acquired pneumonia Pharyngitis/tonsillitis (second-line therapy) | 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 |
Acute bacterial exacerbations of chronic obstructive pulmonary disease | 500 mg once daily for 3 days |
Acute bacterial sinusitis | 500 mg once daily for 3 days |
Genital ulcer disease (chancroid) | One single 1 gram dose |
Non-gonococcal urethritis and cervicitis | One single 1 gram dose |
Gonococcal urethritis and cervicitis | One single 2 gram dose |
ZITHROMAX tablets can be taken with or without food.
Infection* | Recommended Dose/Duration of Therapy |
---|---|
1 see dosing tables below for maximum doses evaluated by indication | |
| |
Acute otitis media | 30 mg/kg as a single dose or 10 mg/kg once daily for 3 days or 10 mg/kg as a single dose on Day 1 followed by 5 mg/kg/day on Days 2 through 5. |
Acute bacterial sinusitis | 10 mg/kg once daily for 3 days. |
Community-acquired pneumonia | 10 mg/kg as a single dose on Day 1 followed by 5 mg/kg once daily on Days 2 through 5. |
Pharyngitis/tonsillitis | 12 mg/kg once daily for 5 days. |
ZITHROMAX for oral suspension can be taken with or without food.
PEDIATRIC DOSAGE GUIDELINES FOR OTITIS MEDIA, ACUTE BACTERIAL SINUSITIS, AND COMMUNITY-ACQUIRED PNEUMONIA
(Age 6 months and above, [see Use in Specific Populations (8.4)])
Based on Body Weight
Dosing Calculated on 10 mg/kg/day Day 1 and 5 mg/kg/day Days 2 to 5. | ||||||
---|---|---|---|---|---|---|
Weight | 100 mg/5 mL | 200 mg/5 mL | Total mL per Treatment Course | Total mg per Treatment Course | ||
Kg | Day 1 | Days 2–5 | Day 1 | Days 2-5 | ||
| ||||||
5 | 2.5 mL; (½ tsp) | 1.25 mL;(¼ tsp) | 7.5 mL | 150 mg | ||
10 | 5 mL; (1tsp) | 2.5 mL; (½ tsp) | 15 mL | 300 mg | ||
20 | 5 mL; (1 tsp) | 2.5 mL; (½ tsp) | 15 mL | 600 mg | ||
30 | 7.5 mL; (1½ tsp) | 3.75 mL; (¾ tsp) | 22.5 mL | 900 mg | ||
40 | 10 mL; (2 tsp) | 5 mL; (1 tsp) | 30 mL | 1200 mg | ||
50 and above | 12.5 mL; (2½ tsp) | 6.25 mL; (1¼ tsp) | 37.5 mL | 1500 mg |
Dosing Calculated on 10 mg/kg/day. | ||||
---|---|---|---|---|
Weight | 100 mg/5 mL | 200 mg/5 mL | Total mL per Treatment Course | Total mg per Treatment Course |
Kg | Days 1–3 | Days 1–3 | ||
| ||||
5 | 2.5 mL; (1/2 tsp) | 7.5 mL | 150 mg | |
10 | 5 mL; (1 tsp) | 15 mL | 300 mg | |
20 | 5 mL (1 tsp) | 15 mL | 600 mg | |
30 | 7.5 mL (1½ tsp) | 22.5 mL | 900 mg | |
40 | 10 mL (2 tsp) | 30 mL | 1200 mg | |
50 and above | 12.5 mL (2 ½ tsp) | 37.5 mL | 1500 mg |
Dosing Calculated on 30 mg/kg as a single dose. | |||
---|---|---|---|
Weight | 200 mg/5 mL | Total mL per Treatment Course | Total mg per Treatment Course |
Kg | 1-Day Regimen | ||
5 | 3.75 mL;(3/4 tsp) | 3.75 mL | 150 mg |
10 | 7.5 mL;(1½ tsp) | 7.5 mL | 300 mg |
20 | 15 mL;(3 tsp) | 15 mL | 600 mg |
30 | 22.5 mL;(4½ tsp) | 22.5 mL | 900 mg |
40 | 30 mL;(6 tsp) | 30 mL | 1200 mg |
50 and above | 37.5 mL;(7½ tsp) | 37.5 mL | 1500 mg |
The safety of re-dosing azithromycin in pediatric patients who vomit after receiving 30 mg/kg as a single dose has not been established. In clinical studies involving 487 patients with acute otitis media given a single 30 mg/kg dose of azithromycin, 8 patients who vomited within 30 minutes of dosing were re-dosed at the same total dose.
Pharyngitis/Tonsillitis: The recommended dose of ZITHROMAX for children with pharyngitis/tonsillitis is 12 mg/kg once daily for 5 days. (See chart below.)
PEDIATRIC DOSAGE GUIDELINES FOR PHARYNGITIS/TONSILLITIS
(Age 2 years and above, [see Use in Specific Populations (8.4)])
Based on Body Weight
Dosing Calculated on 12 mg/kg/day for 5 days. | |||
---|---|---|---|
Weight | 200 mg/5 mL | Total mL per Treatment Course | Total mg per Treatment Course |
Kg | Day 1–5 | ||
8 | 2.5 mL; (½ tsp) | 12.5 mL | 500 mg |
17 | 5 mL; (1 tsp) | 25 mL | 1000 mg |
25 | 7.5 mL; (1½ tsp) | 37.5 mL | 1500 mg |
33 | 10 mL; (2 tsp) | 50 mL | 2000 mg |
40 | 12.5 mL; (2½ tsp) | 62.5 mL | 2500 mg |
Constituting instructions for ZITHROMAX Oral Suspension 300, 600, 900, 1200 mg bottles. The table below indicates the volume of water to be used for constitution:
Amount of water to be added | Total volume after constitution (azithromycin content) | Azithromycin concentration after constitution |
---|---|---|
9 mL (300 mg) | 15 mL (300 mg) | 100 mg/5 mL |
9 mL (600 mg) | 15 mL (600 mg) | 200 mg/5 mL |
12 mL (900 mg) | 22.5 mL (900 mg) | 200 mg/5 mL |
15 mL (1200 mg) | 30 mL (1200 mg) | 200 mg/5 mL |
Shake well before each use. Oversized bottle provides shake space. Keep tightly closed.
After mixing, store suspension at 5° to 30°C (41° to 86°F) and use within 10 days. Discard after full dosing is completed.
[see Indications and Usage (1.1) and Clinical Pharmacology (12.3)]
Infection* | Recommended Dose/Duration of Therapy |
---|---|
| |
Community-acquired pneumonia Pharyngitis/tonsillitis (second-line therapy) | 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 |
Acute bacterial exacerbations of chronic obstructive pulmonary disease | 500 mg once daily for 3 days |
Acute bacterial sinusitis | 500 mg once daily for 3 days |
Genital ulcer disease (chancroid) | One single 1 gram dose |
Non-gonococcal urethritis and cervicitis | One single 1 gram dose |
Gonococcal urethritis and cervicitis | One single 2 gram dose |
ZITHROMAX tablets can be taken with or without food.
Infection* | Recommended Dose/Duration of Therapy |
---|---|
1 see dosing tables below for maximum doses evaluated by indication | |
| |
Acute otitis media | 30 mg/kg as a single dose or 10 mg/kg once daily for 3 days or 10 mg/kg as a single dose on Day 1 followed by 5 mg/kg/day on Days 2 through 5. |
Acute bacterial sinusitis | 10 mg/kg once daily for 3 days. |
Community-acquired pneumonia | 10 mg/kg as a single dose on Day 1 followed by 5 mg/kg once daily on Days 2 through 5. |
Pharyngitis/tonsillitis | 12 mg/kg once daily for 5 days. |
ZITHROMAX for oral suspension can be taken with or without food.
PEDIATRIC DOSAGE GUIDELINES FOR OTITIS MEDIA, ACUTE BACTERIAL SINUSITIS, AND COMMUNITY-ACQUIRED PNEUMONIA
(Age 6 months and above, [see Use in Specific Populations (8.4)])
Based on Body Weight
Dosing Calculated on 10 mg/kg/day Day 1 and 5 mg/kg/day Days 2 to 5. | ||||||
---|---|---|---|---|---|---|
Weight | 100 mg/5 mL | 200 mg/5 mL | Total mL per Treatment Course | Total mg per Treatment Course | ||
Kg | Day 1 | Days 2–5 | Day 1 | Days 2-5 | ||
| ||||||
5 | 2.5 mL; (½ tsp) | 1.25 mL;(¼ tsp) | 7.5 mL | 150 mg | ||
10 | 5 mL; (1tsp) | 2.5 mL; (½ tsp) | 15 mL | 300 mg | ||
20 | 5 mL; (1 tsp) | 2.5 mL; (½ tsp) | 15 mL | 600 mg | ||
30 | 7.5 mL; (1½ tsp) | 3.75 mL; (¾ tsp) | 22.5 mL | 900 mg | ||
40 | 10 mL; (2 tsp) | 5 mL; (1 tsp) | 30 mL | 1200 mg | ||
50 and above | 12.5 mL; (2½ tsp) | 6.25 mL; (1¼ tsp) | 37.5 mL | 1500 mg |
Dosing Calculated on 10 mg/kg/day. | ||||
---|---|---|---|---|
Weight | 100 mg/5 mL | 200 mg/5 mL | Total mL per Treatment Course | Total mg per Treatment Course |
Kg | Days 1–3 | Days 1–3 | ||
| ||||
5 | 2.5 mL; (1/2 tsp) | 7.5 mL | 150 mg | |
10 | 5 mL; (1 tsp) | 15 mL | 300 mg | |
20 | 5 mL (1 tsp) | 15 mL | 600 mg | |
30 | 7.5 mL (1½ tsp) | 22.5 mL | 900 mg | |
40 | 10 mL (2 tsp) | 30 mL | 1200 mg | |
50 and above | 12.5 mL (2 ½ tsp) | 37.5 mL | 1500 mg |
Dosing Calculated on 30 mg/kg as a single dose. | |||
---|---|---|---|
Weight | 200 mg/5 mL | Total mL per Treatment Course | Total mg per Treatment Course |
Kg | 1-Day Regimen | ||
5 | 3.75 mL;(3/4 tsp) | 3.75 mL | 150 mg |
10 | 7.5 mL;(1½ tsp) | 7.5 mL | 300 mg |
20 | 15 mL;(3 tsp) | 15 mL | 600 mg |
30 | 22.5 mL;(4½ tsp) | 22.5 mL | 900 mg |
40 | 30 mL;(6 tsp) | 30 mL | 1200 mg |
50 and above | 37.5 mL;(7½ tsp) | 37.5 mL | 1500 mg |
The safety of re-dosing azithromycin in pediatric patients who vomit after receiving 30 mg/kg as a single dose has not been established. In clinical studies involving 487 patients with acute otitis media given a single 30 mg/kg dose of azithromycin, 8 patients who vomited within 30 minutes of dosing were re-dosed at the same total dose.
Pharyngitis/Tonsillitis: The recommended dose of ZITHROMAX for children with pharyngitis/tonsillitis is 12 mg/kg once daily for 5 days. (See chart below.)
PEDIATRIC DOSAGE GUIDELINES FOR PHARYNGITIS/TONSILLITIS
(Age 2 years and above, [see Use in Specific Populations (8.4)])
Based on Body Weight
Dosing Calculated on 12 mg/kg/day for 5 days. | |||
---|---|---|---|
Weight | 200 mg/5 mL | Total mL per Treatment Course | Total mg per Treatment Course |
Kg | Day 1–5 | ||
8 | 2.5 mL; (½ tsp) | 12.5 mL | 500 mg |
17 | 5 mL; (1 tsp) | 25 mL | 1000 mg |
25 | 7.5 mL; (1½ tsp) | 37.5 mL | 1500 mg |
33 | 10 mL; (2 tsp) | 50 mL | 2000 mg |
40 | 12.5 mL; (2½ tsp) | 62.5 mL | 2500 mg |
Constituting instructions for ZITHROMAX Oral Suspension 300, 600, 900, 1200 mg bottles. The table below indicates the volume of water to be used for constitution:
Amount of water to be added | Total volume after constitution (azithromycin content) | Azithromycin concentration after constitution |
---|---|---|
9 mL (300 mg) | 15 mL (300 mg) | 100 mg/5 mL |
9 mL (600 mg) | 15 mL (600 mg) | 200 mg/5 mL |
12 mL (900 mg) | 22.5 mL (900 mg) | 200 mg/5 mL |
15 mL (1200 mg) | 30 mL (1200 mg) | 200 mg/5 mL |
Shake well before each use. Oversized bottle provides shake space. Keep tightly closed.
After mixing, store suspension at 5° to 30°C (41° to 86°F) and use within 10 days. Discard after full dosing is completed.
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.